knowledge -WSS

knowledge

author：comprehensive 2025-09-27 22:47:43 - browse：32936

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Stop Congress from blocking public access to science

WSS

CRISPR base editing slashes cholesterol levels in monkeys

Some top drug companies are starting to take action on climate

Stop Congress from blocking public access to science

Experts study whether long Covid risk adds up with each reinfection

RSV vaccines may be linked to small increased risk of developing GBS

Will an HIV vaccine ever be a reality?

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Congress gives doctors Medicare pay bump

Tori Bowie and the unacceptable rates of Black maternal death

Stop Congress from blocking public access to science

Moonlake's readout produced a cash windfall. Risks remain

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Sports medicine is finally prioritizing gender equality

Congress extends some pandemic preparedness programs

hotspot

FogPharma raises $145 million in rare Series E round

Study points to new risk in gene therapy death of Terry Horgan

European officials brace for rough respiratory virus season

Stop Congress from blocking public access to science

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

focus

leisure time

hotspot

explore